Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
GNB1 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
GEO DataSets Gene Profile neighbors Chromosome neighbors Homologene neighbors
WWP2 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
NCKAP1L - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
FAF1 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
FGD3 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
SLC43A3 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
ZDHHC5 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
PRKCB - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
M6PR - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
TIAM1 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
MAX - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
RNF13 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
PI4KB - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
MIR4745 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
ACTR2 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
OGT - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
MAPK14 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
MEF2C - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
MIR3620 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
KIAA0100 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on